• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Development of a Pan-H1 Influenza Vaccine

tetano

Editor, Senior Moderator
J Virol. 2018 Sep 5. pii: JVI.01349-18. doi: 10.1128/JVI.01349-18. [Epub ahead of print]
[h=1]Development of a Pan-H1 Influenza Vaccine.[/h] Darricarr?re N[SUP]1[/SUP], Pougatcheva S[SUP]2[/SUP], Duan X[SUP]2[/SUP], Rudicell RS[SUP]1[/SUP], Chou TH[SUP]1[/SUP], DiNapoli J[SUP]2[/SUP], Ross TM[SUP]3[/SUP], Alefantis T[SUP]2[/SUP], Vogel TU[SUP]2[/SUP], Kleanthous H[SUP]2[/SUP], Wei CJ[SUP]4[/SUP], Nabel GJ[SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The efficacy of current seasonal influenza vaccines varies greatly, depending on the match to circulating viruses. Though most vaccines elicit strain-specific responses, some present cross-reactive epitopes that elicit antibodies against diverse viruses and remain unchanged and effective for several years (1). To determine whether combinations of specific H1 HA antigens stimulate immune responses that protect against diverse H1 influenza, we evaluated the antibody responses elicited by HA-ferritin nanoparticles derived from six evolutionarily divergent H1 sequences and two computationally optimized broadly reactive antigen (COBRA) HA antigens. Humoral responses were assessed against a panel of 16 representative influenza virus strains from the past 80 years. HAs from the strains A/NewCaledonia/20/1999 (NC99), A/California/04/2009 (CA09), A/HongKong/117/1977 (HK77) or COBRA-X6 and P1 elicited neutralization against diverse strains, and a combination of these three wildtype HA- or two COBRA HA-nanoparticles conferred significant additional breadth beyond that observed with any individual strain. Therefore, combinations of H1 HAs may potentially constitute a pan-H1 influenza vaccine.IMPORTANCE Seasonal influenza vaccines elicit strain-specific immune responses designed to protect against circulating viruses. Because these vaccines often show limited efficacy, the search for a broadly protective seasonal vaccine remains a priority. Among different influenza virus subtypes, H1N1 has long been circulating in humans and has caused pandemic outbreaks. In order to assess the potential of a multivalent HA combination vaccine to improve the breadth of protection against divergent H1N1 viruses, HA-ferritin nanoparticles were made and evaluated in mice against a panel of historical and contemporary influenza virus strains. Trivalent combinations of H1-nanoparticles improved the breadth of immunity against divergent H1 influenza viruses.


PMID: 30185594 DOI: 10.1128/JVI.01349-18
Free full text
 
Back
Top Bottom